Market Overview

UPDATE: Cantor Fitzgerald Raises PT on Celldex Therapeutics on Upcoming CDX-011 Trial

Related CLDX
Long-term Survival Benefit Demonstrated in Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma
Celldex Therapeutics Reports Presentation of Varlilumab Mechanism Data at SITC Annual Meeting '15

In a report published Friday, Cantor Fitzgerald reiterated its Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and raised its price target from $13.00 to $16.00.

Cantor Fitzgerald noted, “We are raising our price target on shares of Celldex to $16 from $13 based on our assessment that the company is likely to see revenues from both CDX-011 and rindopepimut in 2016 versus our original forecast of 2017. We have been conservative in our modeling but based on the current timeline of completion of clinical trials and assumption of FDA priority review, we are now modeling revenue in 2016 and 2017 of $68 and $300 million, respectively and our EPS forecasts for those years are now ($0.15) and $1.60.”

Celldex Therapeutics closed on Thursday at $10.49.

Latest Ratings for CLDX

Mar 2015JefferiesMaintainsBuy
Mar 2015Cantor FitzgeraldMaintainsBuy
Sep 2014Cowen & CompanyInitiates Coverage onOutperform

View More Analyst Ratings for CLDX
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Analyst Ratings


Related Articles (CLDX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters